Tema Oncology ETF (NASDAQ:CANC) Short Interest Up 50.0% in September

Tema Oncology ETF (NASDAQ:CANC) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 600 shares, an increase of 50.0% from the August 31st total of 400 shares. Based on an average trading volume of 7,300 shares, the days-to-cover ratio is currently 0.1 days.

Hedge Funds Weigh In On Tema Oncology ETF

A hedge fund recently bought a new stake in Tema Oncology ETF stock. Thrivent Financial for Lutherans acquired a new stake in Tema Oncology ETF (NASDAQ:CANC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 319,376 shares of the company’s stock, valued at approximately $8,616,000. Thrivent Financial for Lutherans owned about 19.01% of Tema Oncology ETF at the end of the most recent quarter.

Tema Oncology ETF Trading Up 0.3 %

Shares of Tema Oncology ETF stock opened at $28.32 on Friday. The company has a fifty day simple moving average of $28.95 and a 200-day simple moving average of $27.84. The stock has a market cap of $47.58 million, a price-to-earnings ratio of 26.86 and a beta of 1.11. Tema Oncology ETF has a 12-month low of $21.26 and a 12-month high of $30.11.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.